Pfizer-BioNTech seeks USFDA authorisation for COVID vaccine for kids under 5 years

No COVID-19 shot is yet approved for children in that age group in most parts of the world.

Published On 2022-06-03 06:00 GMT   |   Update On 2022-06-03 12:04 GMT

New Delhi: Pfizer Inc and partner BioNTech have completed the filing with the U.S. drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.The filing with the U.S. Food and Drug Administration (FDA), completed on Wednesday, included data showing three lower-dose shots of the vaccine generated a strong immune response in children as young as 6 months...

Login or Register to read the full article

New Delhi: Pfizer Inc and partner BioNTech have completed the filing with the U.S. drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.

The filing with the U.S. Food and Drug Administration (FDA), completed on Wednesday, included data showing three lower-dose shots of the vaccine generated a strong immune response in children as young as 6 months of age.

No COVID-19 shot is yet approved for children in that age group in most parts of the world. It remains unclear how many parents will get their young ones vaccinated as demand has been low in kids aged 5 to 11.

Pfizer and BioNTech on May 23 said their trial showed a 3 microgram version of the vaccine generated a similar immune response in under 5-year-olds as two doses of 30 micrograms each in 16 to 25-year-olds in an earlier trial.

Read also: Pfizer third COVID vaccine shot over 80 percent effective against Omicron in kids under 5

Rival Moderna in March released trial data that showed a two-dose formulation of its vaccine was safe and generated a similar immune response in young children as in adults.

The FDA's independent advisers will discuss the two applications in a meeting set for June 15.

Read also: Pfizer-BioNTech COVID booster authorized in Canada for 16, 17-year-olds

Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News